Uncommon EGFR Mutations in Non–Small Cell Lung Cancer - Episode 11

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

Partner | Cancer Centers | <b>The University of Texas MD Anderson Cancer Center</b>

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

EP. 1: Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
EP. 2: Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer
EP. 3: Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP. 4: Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities
EP. 5: Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer
EP. 6: Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP. 7: Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC
EP. 8: Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
EP. 9: Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC
EP. 10: Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC
Now Viewing
EP. 11: Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
EP. 12: Uncommon EGFR Mutations in Non–Small Cell Lung Cancer

Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.

OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Takeda, we had the pleasure of speaking with John V. Heymach, MD, PhD, chair, professor, and David Bruton, Jr Chair in Cancer Research in the Department of Thoracic/Head and Neck Medical Oncology, and professor in the Department of Cancer Biology, Division of Cancer Medicine at The University of MD Anderson Cancer Center, to discuss EGFR 20 insertion–mutated non–small cell lung cancer (NSCLC).

In our exclusive interview, Heymach discussed the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.